Search research articles
Contact Us
Filters
Showing results (31-40 of 44) with videos related to
Page
of 5
Sort By:
Journal of Controlled Release : Official Journal of the Controlled Release Society
|
November 2, 2025
Hydrogel formulations for sustained-release of broadly neutralizing antibodies
Carolyn K Jons, Catherine M Kasse, Bryan T Mayer, et al.
Vaccine
|
June 8, 2021
Safety and immunogenicity of an HIV-1 gp120-CD4 chimeric subunit vaccine in a phase 1a randomized controlled trial
Joel V Chua, Charles Davis, Jennifer S Husson, et al.
Biorxiv : the Preprint Server for Biology
|
June 12, 2025
Engineering Sustained-Release Broadly Neutralizing Antibody Formulations
Carolyn K Jons, Catherine M Kasse, Bryan T Mayer, et al.
Pharmaceutics
|
May 25, 2024
Impact of LS Mutation on Pharmacokinetics of Preventive HIV Broadly Neutralizing Monoclonal Antibodies: A Cross-Protocol Analysis of 16 Clinical Trials in People without HIV
Bryan T Mayer, Lily Zhang, Allan C deCamp, et al.
Annals of the New York Academy of Sciences
|
August 23, 2018
Sm-p80-based schistosomiasis vaccine: double-blind preclinical trial in baboons demonstrates comprehensive prophylactic and parasite transmission-blocking efficacy
Weidong Zhang, Adebayo J Molehin, Juan U Rojo, et al.
Immunity
|
September 18, 2020
A Potent Anti-Malarial Human Monoclonal Antibody Targets Circumsporozoite Protein Minor Repeats and Neutralizes Sporozoites in the Liver
Lawrence T Wang, Lais S Pereira, Yevel Flores-Garcia, et al.
Nature Communications
|
March 23, 2024
Author Correction: High monoclonal neutralization titers reduced breakthrough HIV-1 viral loads in the Antibody Mediated Prevention trials
Daniel B Reeves, Bryan T Mayer, Allan C deCamp, et al.
Nature Communications
|
December 14, 2023
High monoclonal neutralization titers reduced breakthrough HIV-1 viral loads in the Antibody Mediated Prevention trials
Daniel B Reeves, Bryan T Mayer, Allan C deCamp, et al.
Nature Medicine
|
May 13, 2022
Safety and antiviral activity of triple combination broadly neutralizing monoclonal antibody therapy against HIV-1: a phase 1 clinical trial
Boris Julg, Kathryn E Stephenson, Kshitij Wagh, et al.
Biorxiv : the Preprint Server for Biology
|
October 28, 2024
A comprehensive engineering strategy improves potency and manufacturability of a near pan-neutralizing antibody against HIV
Mohammad M Sajadi, Abdolrahim Abbasi, Zahra Rikhtegaran Tehrani, et al.
Page
of 5
Search research articles
Search
Showing results (31-40 of 44) with videos related to
Sort By:
Page
of 5
Journal of Controlled Release : Official Journal of the Controlled Release Society
|
November 2, 2025
Hydrogel formulations for sustained-release of broadly neutralizing antibodies
Carolyn K Jons, Catherine M Kasse, Bryan T Mayer, et al.
Vaccine
|
June 8, 2021
Safety and immunogenicity of an HIV-1 gp120-CD4 chimeric subunit vaccine in a phase 1a randomized controlled trial
Joel V Chua, Charles Davis, Jennifer S Husson, et al.
Biorxiv : the Preprint Server for Biology
|
June 12, 2025
Engineering Sustained-Release Broadly Neutralizing Antibody Formulations
Carolyn K Jons, Catherine M Kasse, Bryan T Mayer, et al.
Pharmaceutics
|
May 25, 2024
Impact of LS Mutation on Pharmacokinetics of Preventive HIV Broadly Neutralizing Monoclonal Antibodies: A Cross-Protocol Analysis of 16 Clinical Trials in People without HIV
Bryan T Mayer, Lily Zhang, Allan C deCamp, et al.
Annals of the New York Academy of Sciences
|
August 23, 2018
Sm-p80-based schistosomiasis vaccine: double-blind preclinical trial in baboons demonstrates comprehensive prophylactic and parasite transmission-blocking efficacy
Weidong Zhang, Adebayo J Molehin, Juan U Rojo, et al.
Immunity
|
September 18, 2020
A Potent Anti-Malarial Human Monoclonal Antibody Targets Circumsporozoite Protein Minor Repeats and Neutralizes Sporozoites in the Liver
Lawrence T Wang, Lais S Pereira, Yevel Flores-Garcia, et al.
Nature Communications
|
March 23, 2024
Author Correction: High monoclonal neutralization titers reduced breakthrough HIV-1 viral loads in the Antibody Mediated Prevention trials
Daniel B Reeves, Bryan T Mayer, Allan C deCamp, et al.
Nature Communications
|
December 14, 2023
High monoclonal neutralization titers reduced breakthrough HIV-1 viral loads in the Antibody Mediated Prevention trials
Daniel B Reeves, Bryan T Mayer, Allan C deCamp, et al.
Nature Medicine
|
May 13, 2022
Safety and antiviral activity of triple combination broadly neutralizing monoclonal antibody therapy against HIV-1: a phase 1 clinical trial
Boris Julg, Kathryn E Stephenson, Kshitij Wagh, et al.
Biorxiv : the Preprint Server for Biology
|
October 28, 2024
A comprehensive engineering strategy improves potency and manufacturability of a near pan-neutralizing antibody against HIV
Mohammad M Sajadi, Abdolrahim Abbasi, Zahra Rikhtegaran Tehrani, et al.
Page
of 5